FilingReader Intelligence
Zhifei Bio starts 26-valent pneumococcal vaccine trial in Australia
July 21, 2025 at 12:31 PM UTC•By FilingReader AI
Chongqing Zhifei Biological Products has initiated Phase I clinical trials in Australia for its 26-valent pneumococcal conjugate vaccine, targeting individuals aged 60 and above.
The company states no other 26-valent pneumococcal conjugate vaccines are currently in clinical research or approved for market.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Chongqing Zhifei Biological Products publishes news
Free account required • Unsubscribe anytime